Adempas

Country: Нови Зеланд

Језик: Енглески

Извор: Medsafe (Medicines Safety Authority)

Активни састојак:

Riociguat 1mg

Доступно од:

Bayer New Zealand Limited

INN (Међународно име):

Riociguat 1 mg

Дозирање:

1 mg

Фармацеутски облик:

Film coated tablet

Састав:

Active: Riociguat 1mg Excipient: Crospovidone Hyprolose Hypromellose   Iron oxide yellow Lactose monohydrate Magnesium stearate Microcrystalline cellulose Propylene glycol Purified water Sodium laurilsulfate Titanium dioxide

Тип рецептора:

Prescription

Произведен од:

Bayer AG

Терапеутске индикације:

Pulmonary arterial hypertension Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, III or IV symptoms.

Резиме производа:

Package - Contents - Shelf Life: Blister pack, PP/Al - 42 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, PP/Al - 84 tablets - 36 months from date of manufacture stored at or below 30°C

Датум одобрења:

2014-06-25